Objectives: To assess low dose altepase outcome and safety in comparison with a standard-
dose regimen for acute ischemic stroke treatment in Egyptian patients. Materials: An …

Background Thrombolytic therapy for acute ischemic stroke with a lower-than-standard dose
of intravenous alteplase may improve recovery along with a reduced risk of intracerebral …

Objective: This study analyzed the efficacy and safety of low-dose and standard-dose
alteplase intravenous thrombolytic therapy for acute ischemic stroke (AIS). Methods: Patients …

Object The purpose of this study was to investigate the safety and efficacy of intravenous low-
dose alteplase for acute ischemic stroke patients with relative contraindications. Methods …

Background: Rates of intracranial hemorrhage (ICH) after intravenous thrombolysis (IVT)
differ depending on ethnicity, one reason that few Eastern countries have approved a lower …

Background Intravenous thrombolysis with alteplase is the only approved treatment for acute
ischemic stroke, but its efficacy and safety when administered more than 3 hours after the …

Objective To investigate the comparative efficacy and safety of the low-dose versus standard-
dose alteplase using real-world acute stroke registry data from Asian countries. Methods …

Background Thrombolysis with intravenous alteplase has been proven an effective
treatment for patients with acute ischemic stroke in randomized clinical trials. In daily …

Abstract Introduction South Asia is responsible for more than 40% of the stroke burden and
stroke mortality in the developing world. South Asia, which is home to one-fourth of the …

Background For the last 15 years, alteplase (recombinant tissue plasminogen activator) has
been used widely throughout the world for the treatment of acute ischemic stroke. Although …